Kerry Anne Rogers, MD

Videos

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up

11/08/2024

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

Kerry Rogers, MD, provides a...

11/08/2024

Journal of Clinical Pathways

Conference Coverage

Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?

09/23/2024

;

At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.

At the 2024 SOHO meeting, Kerry...

09/23/2024

Oncology

Videos

Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL

06/22/2023

Kerry Anne Rogers , MD;

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.

At the 2023 ASCO Annual Meeting...

06/22/2023

Oncology

Conference Coverage

Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?

09/23/2024

;

At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.

At the 2024 SOHO meeting, Kerry...

09/23/2024

Oncology